Innovations
Commented by André Will-Laudien on October 24th, 2025 | 07:35 CEST
BioNxt Solutions advances sublingual MS therapy into decisive development phase
BioNxt Solutions is on the verge of a decisive step in the development of its novel sublingual cladribine formulation for the treatment of multiple sclerosis. Following successful small-animal studies, the Company is now launching a large-scale animal study to optimize dosage ahead of the planned human bioequivalence study in 2026. The orally soluble thin-film technology is designed to enable faster drug absorption, greater bioavailability, and easier administration. At the same time, BioNxt is securing patent protection in key global markets, further strengthening its position in the competitive field of advanced drug delivery systems. With its focus on patient-friendly, precise, and effective therapies, BioNxt could set a new standard in MS treatment. A promising setup for the coming months. What opportunities does the Company offer dynamic investors?
Read
Commented by Nico Popp on October 22nd, 2025 | 07:00 CEST
Important piece of the puzzle in the fight against cancer: Vidac Pharma, Roche, Merck & Co.
The pharmaceutical market is enormous - and continues to grow. Market research institute Evaluate forecasts an increase to around USD 1.7 trillion by 2030, representing an annual growth rate of 7.7%. Oncology promises the highest sales, at around USD 300 billion. However, there is no single approach. Instead, new modalities and technologies such as antibody-drug conjugates (ADCs), cell and gene therapies, and radiopharmaceuticals are transforming the industry and gaining significant traction. One thing is clear: progress in the biotech sector is increasingly achieved through the combination of active ingredients and technologies. What role does the biotech company Vidac Pharma play in this?
Read
Commented by Armin Schulz on October 20th, 2025 | 07:05 CEST
Why this structural change in medicine makes Novo Nordisk, PanGenomic Health, and Pfizer must-haves
The medicine of tomorrow does not think in terms of diseases but in terms of opportunities. A radical shift from repair to proactive prevention is revolutionizing the healthcare sector and opening up massive areas of growth. The focus is on personalized, data-driven solutions that improve quality of life and combat widespread diseases costing billions. This structural transformation is creating clear winners, led by pioneers who have mastered the new logic of the healthcare market. Three companies that embody this trend and make it tangible for investors are Novo Nordisk, PanGenomic Health, and Pfizer.
Read
Commented by Stefan Feulner on October 13th, 2025 | 07:35 CEST
BioNxt Solutions – Attack on new highs
After global stock markets had been on an upward trajectory in recent weeks, US President Donald Trump caused some irritation with a post on his social media platform, "Truth Social." The escalating trade dispute with China, the world's second-largest economy, caused the already overvalued markets to falter. The DAX lost just under 1.8% at the end of the week, while the Nasdaq technology index suffered significantly more, losing just under 4.3%. In the coming weeks, stock picking is likely to take center stage. Against this backdrop, BioNxt Solutions, a life sciences company specializing in innovative technologies for next-generation drug delivery, was able to shine with fundamental milestones and buck the negative trend.
Read
Commented by André Will-Laudien on October 8th, 2025 | 07:30 CEST
BioNxt Solutions – A small biotech gem with huge potential
Modern medicine is undergoing a paradigm shift - and BioNxt Solutions could emerge as one of its key pioneers. The German-Canadian biotech company is developing innovative drug delivery platforms designed to make existing medications more effective, safer, and more patient-friendly. Whether for obesity, multiple sclerosis, or cancer, BioNxt is targeting several multi-billion-dollar markets with disruptive potential. Backed by patented technologies and an agile development strategy, BioNxt is laying the foundation for above-average growth and attractive licensing models. For investors, this could be a rare chance to get in early on what could be the next big thing in healthcare innovation.
Read
Commented by Armin Schulz on October 7th, 2025 | 07:20 CEST
Cancer research with billion-dollar potential: How Bayer, Vidac Pharma, and BioNTech could come into play
The oncology market is booming like no other. Driven by technological quantum leaps and, unfortunately, rising case numbers, cancer treatment is becoming a highly lucrative innovation engine. The sector is growing at double-digit rates every year. Experts predict that the global market volume will break the USD 1 trillion mark within the next decade. No wonder, then, that the race for the next therapeutic breakthroughs in personalized medicines and AI-supported active ingredients is heating up. Investors are focusing not only on established players like Bayer, but also on up-and-coming specialists such as Vidac Pharma and mRNA pioneers like BioNTech.
Read
Commented by Armin Schulz on October 3rd, 2025 | 07:05 CEST
BioNxt Solutions' pharmaceutical revolution: New ways of administering blockbuster drugs
Imagine chemotherapy without severe side effects or a blockbuster drug without needles. What sounds like a pipe dream is now becoming reality thanks to innovative drug delivery systems. They are revolutionizing billion-dollar markets from oncology to obesity therapy and laying the foundation for exponential growth. For investors, this technological breakthrough opens up a unique investment window. BioNxt Solutions is at the forefront of this movement.
Read
Commented by Nico Popp on September 26th, 2025 | 07:30 CEST
AI is conquering increasingly more areas: SAP and Amazon are targeting small and mid-sized businesses, while NetraMark is winning over the biotech industry
Will AI become our new god? This question is currently being explored in depth by the German philosopher Markus Gabriel in a well-known German podcast. And although the question may cause unease for many, Gabriel's conclusions are ultimately anything but pessimistic. SAP and Amazon are also looking to the future with optimism: Together with OpenAI, they are now building an AI infrastructure in Germany. The goal: to enable public authorities and companies to use the latest AI tools in a legally compliant manner, without European data leaving the continent. The initiative demonstrates that AI will conquer many more areas in the coming years. One of these areas is medical research. The innovative company NetraMark is using its AI solution to deliver faster results and lower costs for future-focused projects, such as the fight against cancer.
Read
Commented by Armin Schulz on September 22nd, 2025 | 07:40 CEST
BioNxt Solutions: Your chance to get in early on the next biotech blockbuster
Imagine a cancer treatment that doesn't affect the whole body, but instead acts only at the tumor site. Or a treatment for multiple sclerosis that no longer needs to be swallowed, but simply dissolves under the tongue. What sounds like a dream of the future is already being pursued with full force by the German-Canadian biotech company BioNxt Solutions. The Company is developing two innovative platform technologies that aim to solve some of the biggest challenges in modern medicine. For investors, this opens up extraordinary opportunities.
Read
Commented by Nico Popp on September 18th, 2025 | 07:05 CEST
Understanding metabolism, generating returns: Vidac Pharma, Roche, AstraZeneca
In the search for new treatments against diseases, researchers agree on one thing: the holy grail is unlikely to be found. Instead, it is incremental improvements and combination therapies that promise progress in complex diseases such as cancer. Cell metabolism is considered a promising approach, for example, in cancer, when the metabolism of a cancer cell is disrupted, the cell dies. In this article, we present current approaches and also discuss a biotechnology company that is wholly dedicated to cellular metabolism.
Read